MedTrace Logo

Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis

NCT01705457 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-10-12

No results posted yet for this study

Summary

The aim of this study is the comparison between the effects of supplementation with 25000 IU preformed vitamin A (retinyl palmitate)on retinoic acid receptor and retinoic x receptor expression.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

Dietary Supplement: vitamin A

25000 IU/day vitamin A for 6 months 1 Cap/Day 1 cap placebo/day for 6 month

DRUG

placebo

Sponsors & Collaborators

  • Tehran University of Medical Sciences

    lead OTHER

Principal Investigators

  • Ali Akbar saboor Yaraghi, PhD · Tehran University of Medical Sciences

  • Sama Bitarafan, MD, PhD student · Tehran University of Medical Siences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2013-02-28
Completion
2013-08-31

Countries

  • Iran

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01705457 on ClinicalTrials.gov